Close Menu

NEW YORK (360Dx) – Chembio Diagnostics announced after the close of the market on Monday a sharp rise in its preliminary third quarter revenues, a planned acquisition of OpTricon, and that it has commenced an underwritten public offering of $25 million of its common stock.

The Medford, New York-based point-of-care diagnostic firm said that revenues for the third quarter are expected to be in the range of $9.2 million and $9.4 million, which would represent year-over-year growth of 21 to almost 24 percent from $7.6 million in revenues in Q3 2017.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.